A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Public ClinicalTrials.gov record NCT05263999. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination With Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI involvement, in combination with corticosteroids
Study identification
- NCT ID
- NCT05263999
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 158 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 28, 2022
- Primary completion
- Apr 21, 2025
- Completion
- May 11, 2025
- Last update posted
- Jun 16, 2025
2022 – 2025
United States locations
- U.S. sites
- 38
- U.S. states
- 20
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| City of Hope | Duarte | California | 91010 | — |
| University of California, San Diego (UCSD) - Moores Cancer Center | La Jolla | California | 92093 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| University of California, Los Angeles (UCLA) - Medical Center | Los Angeles | California | 90059 | — |
| Stanford Cancer Center | Stanford | California | 94305 | — |
| AdventHealth Orlando | Orlando | Florida | 32804 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | — |
| The University of Chicago Medical Center (UCMC) | Chicago | Illinois | 60637 | — |
| Loyola University Chicago, performing research at Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Tulane University Medical Center | New Orleans | Louisiana | 70112 | — |
| University of Maryland Medical Center | Baltimore | Maryland | 21201 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Spectrum Health | Grand Rapids | Michigan | 49503 | — |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | — |
| John Theurer Cancer Center At Hackensack UMC | Hackensack | New Jersey | 07601 | — |
| Rutgers Cancer Institute of NJ | New Brunswick | New Jersey | 08901 | — |
| Northwell Health | Lake Success | New York | 11042 | — |
| David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Stony Brook University Medical Center | Stony Brook | New York | 11794 | — |
| University of North Carolina (UNC) | Chapel Hill | North Carolina | 27514 | — |
| Wake Forest | Winston-Salem | North Carolina | 27157 | — |
| Oncology Hematology in Cincinnati | Cincinnati | Ohio | 45242 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| The Ohio State University (OSU) | Columbus | Ohio | 43201 | — |
| Oregon Health & Science University (OHSU) | Portland | Oregon | 97239 | — |
| University of Pennsylvania Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Sarah Cannon Research Institute, LLC (SCRI) | Nashville | Tennessee | 37203 | — |
| Baylor Scott & White Research Institute | Dallas | Texas | 75246 | — |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 80 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05263999, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 16, 2025 · Synced Sep 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05263999 live on ClinicalTrials.gov.